<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919890</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-7684-01</org_study_id>
    <nct_id>NCT03919890</nct_id>
  </id_info>
  <brief_title>A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers</brief_title>
  <official_title>A First-in-human, Randomised, Placebo-controlled, Double-blind, Single and Multiple Dose Study to Explore the Safety, Tolerability, PK and PD of Oral Doses of ONO-7684 in Healthy Subjects Under Fed and Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in human study to determine the safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of ONO-7684 in healthy adult volunteers. This study will be conducted in 2&#xD;
      parts: Part A is a single-ascending dose and Part B is a multiple-ascending dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to obtain safety, tolerability, pharmacokinetic and pharmacodynamic data when&#xD;
      ONO-7684 is administered orally as single doses and as multiple doses to healthy subjects.&#xD;
      The study will consist of 2 parts: A single ascending dose (SAD) phase (Part A); a multiple&#xD;
      ascending dose (MAD) phase (Part B). One cohort of Part A will receive ONO-7684 under both&#xD;
      fasted and fed conditions to investigate the effect of food.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Actual">August 23, 2019</completion_date>
  <primary_completion_date type="Actual">August 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs (Part A &amp; B)</measure>
    <time_frame>Part A: Day 1-4 &amp; Follow-up and Part B: Day 1-15, 17 &amp; Follow up</time_frame>
    <description>Pulse rate (bpm), systolic and diastolic blood pressure (mmHg), Respiratory rate (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes observed on 12-lead electrocardiogram (ECG) (Part A &amp; B)</measure>
    <time_frame>Part A: Day 1-4 &amp; Follow up &amp; Part B: Day 1,3,5,7,9,11,14,17 &amp; Follow up</time_frame>
    <description>Ventricular rate (beats/min), PR interval (msec), QRS interval (msec), QT (msec), QTcF interval (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in cardiac telemetry (Part A only)</measure>
    <time_frame>Part A: From 0.5-1 hours pre-dose until 12 hours after dosing at Day 1</time_frame>
    <description>Number of participants with cardiac telemetry abnormalities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in physical examination (Part A &amp; B)</measure>
    <time_frame>Part A: Day -1, 1-4 &amp; Follow-up and Part B: Day-1, 1-17 &amp; Follow up</time_frame>
    <description>Number of participants with physical examination abnormalities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory safety tests (haematology, biochemistry and urinalysis) (Part A &amp; B)</measure>
    <time_frame>Part A: Day-1, 1-4 &amp; Follow up and Part B: Day-1, 1-17 &amp; Follow up</time_frame>
    <description>Number of participants with abnormalities in laboratory safety tests will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AE) (Part A &amp; B)</measure>
    <time_frame>Part A: Day-1, 1-4 &amp; Follow up and Part B: Day-1, 1-17 &amp; Follow up</time_frame>
    <description>AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 1 and Day 14</time_frame>
    <description>Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (tmax)</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 1 and Day 14</time_frame>
    <description>Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUClast)</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 14</time_frame>
    <description>Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUCinf)</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 14</time_frame>
    <description>Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUCt)</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 1</time_frame>
    <description>Assessment of the area under the curve of concentration of ONO-7684 and 3-hydroxybenzoic acid - time from zero up to a definitive time, t in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (%AUCextrap)</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 14</time_frame>
    <description>Assessment of the percentage of AUCâˆž extrapolated from tlast to infinity of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (t1/2)</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 14</time_frame>
    <description>Assessment of the elimination half-time of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (CL/F)</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Assessment of the apparent clearance rate of ONO-7684 and 3-hydroxybenzoic acid in Part A only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Terminal Rate Constant)</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Assessment of the terminal rate constant (slowest rate constant of the disposition) of ONO-7684 and 3-hydroxybenzoic acid in plasma in Part A only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Aet)</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Assessment of the amount of ONO-7684 excreted in urine over the period of sample collection in Part A only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (fe/F)</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Assessment of the fraction of orally administered ONO-7684 excreted into urine in Part A only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (CLr)</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Assessment of the renal clearance of ONO-7684 from plasma in Part A only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (Ctrough)</measure>
    <time_frame>Day 1 through Day 14</time_frame>
    <description>Assessment of the trough plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Part B only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (AUCtau)</measure>
    <time_frame>Day 14</time_frame>
    <description>Assessment of the area under the plasma concentration of ONO-7684 and 3-hydroxybenzoic acid -time during a dosing interval in Part B only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (CLSS/F)</measure>
    <time_frame>Day 14</time_frame>
    <description>Assessment of total clearance of ONO-7684 from plasma after oral administration in Part B only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (VZ/F)</measure>
    <time_frame>Day 14</time_frame>
    <description>Assessment of apparent volume of distribution of ONO-7684 after non-intravenous administration calculated at steady state in Part B only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (change from baseline in aPTT activity) in serum</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 1 through Day 17</time_frame>
    <description>Assessment of the effect of ONO-7684 in activated partial thromboplastin time in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (change from baseline in PT activity) in serum</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 1 through Day 17</time_frame>
    <description>Assessment of the effect of ONO-7684 in prothrombin time in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (change from baseline in PT-INR activity) in serum</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 1 through Day 17</time_frame>
    <description>Assessment of the effect of ONO-7684 in prothrombin time-international normalised ratio in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (change from baseline in FXIa activity) in serum</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 1 through Day 17</time_frame>
    <description>Assessment of the effect of ONO-7684 in blood coagulation activated factor XI in Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (correlation of aPTT and FXIa activity) in serum</measure>
    <time_frame>Part A: Day 1 through Day 4. Part B: Day 1 through Day 17</time_frame>
    <description>Assessment of the effect of ONO-7684 in the correlation of activated partial thromboplastin time to blood coagulation activated factor XI in Parts A and B</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>ONO-7684 Part A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of ONO-7684 or placebo orally under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-7684 Placebo Part A1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending doses of ONO-7684 or placebo orally under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-7684 Part A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of ONO-7684 or placebo orally under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-7684 Placebo Part A2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of ONO-7684 or placebo orally under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-7684 Part B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive multiple doses of ONO-7684 or placebo orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-7684 Placebo Part B1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive multiple doses of ONO-7684 or placebo orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7684</intervention_name>
    <description>Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3</description>
    <arm_group_label>ONO-7684 Part A1</arm_group_label>
    <arm_group_label>ONO-7684 Part A2</arm_group_label>
    <arm_group_label>ONO-7684 Part B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7684 Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>ONO-7684 Placebo Part A1</arm_group_label>
    <arm_group_label>ONO-7684 Placebo Part A2</arm_group_label>
    <arm_group_label>ONO-7684 Placebo Part B1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-55 years&#xD;
&#xD;
          2. normotensive male volunteers, or female volunteers of non-childbearing potential (Part&#xD;
             B only)&#xD;
&#xD;
          3. body mass index 18.0-30.0 kg/m2&#xD;
&#xD;
          4. deemed healthy on the basis of a clinical history, physical examination, ECG, vital&#xD;
             signs, and laboratory tests of blood and urine&#xD;
&#xD;
          5. registered with a General Practitioner (GP) in the UK&#xD;
&#xD;
          6. agree to use an effective method of contraception&#xD;
&#xD;
          7. able to give fully informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive tests for hepatitis B &amp; C, HIV&#xD;
&#xD;
          2. severe adverse reaction to any drug&#xD;
&#xD;
          3. sensitivity to trial medication&#xD;
&#xD;
          4. drug or alcohol abuse&#xD;
&#xD;
          5. current smoker or use of nicotine containing products in the previous 6 months&#xD;
&#xD;
          6. vegetarians or vegans, or unwilling to eat a high-fat breakfast (Part A food effect&#xD;
             cohorts only)&#xD;
&#xD;
          7. use of strong CYP3A4/5 or P-glycoprotein inhibitors or inducers, anticoagulants,&#xD;
             antiplatelet agents, non-steroidal anti-inflammatory drugs and/or acetylsalicylic acid&#xD;
             within the previous 30 days&#xD;
&#xD;
          8. prescription or over-the-counter medication, vitamins, herbal treatments or dietary&#xD;
             supplements within the previous 7 days (with the exception of paracetamol&#xD;
             [acetaminophen])&#xD;
&#xD;
          9. participation in other clinical trials of unlicensed medicines, or loss of more than&#xD;
             400 mL blood, within the previous 3 months or plan to donate blood or blood products&#xD;
             in the 3 months after the trial&#xD;
&#xD;
         10. vital signs outside the acceptable range&#xD;
&#xD;
         11. clinically relevant abnormal findings at the screening assessment (including&#xD;
             creatinine clearance, haemoglobin levels and QTcF)&#xD;
&#xD;
         12. acute or chronic illness&#xD;
&#xD;
         13. clinically relevant abnormal medical history or concurrent medical condition&#xD;
&#xD;
         14. objection by GP&#xD;
&#xD;
         15. possibility that volunteer will not cooperate&#xD;
&#xD;
         16. pre-menopausal females who are pregnant or lactating, or who are of childbearing&#xD;
             potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

